Peter Nassar, MD
Pulmonary Disease · Jacksonville, FLNPI 1629157243
Payments from drug & device makers
Across 356 payments — averaging $395.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$114K
- Inspire Medical Systems, Inc.$24K
- Harmony Biosciences LLC$631
- Avadel CNS Pharmaceuticals, LLC$476
- Axsome Therapeutics, Inc.$411
- Eisai Inc.$193
- plus $1K from 12 others
What the payments were for
- Consulting fees$18,18813%
- Speaking & faculty fees$95,37068%
- Travel & lodging$16,81712%
- Food & beverage$9,9707%
- Education$3890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 204 | $114,214 |
| Inspire Medical Systems, Inc. | 48 | $23,779 |
| Harmony Biosciences LLC | 25 | $631 |
| Avadel CNS Pharmaceuticals, LLC | 10 | $476 |
| Axsome Therapeutics, Inc. | 17 | $411 |
| Eisai Inc. | 15 | $193 |
| Fisher & Paykel Healthcare Inc | 10 | $170 |
| Idorsia Pharmaceuticals US Inc | 9 | $155 |
| Itamar Medical Inc | 3 | $127 |
| Novo Nordisk | 1 | $121 |
| Regeneron Healthcare Solutions, Inc. | 1 | $120 |
| Amgen | 1 | $109 |
| Merck | 4 | $69 |
| Lilly USA, LLC | 3 | $64 |
| Philips North America LLC | 1 | $32 |
| Pfizer | 2 | $29 |
| Resmed Corp | 1 | $20 |
| Aytu Biopharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$140,734 in reported general payments places this provider in the 85th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Modafinil | 22 | $7,199 |
| Armodafinil | 24 | $1,229 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 29 | $918 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 51 | $729 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $585 |
| Zolpidem Tartrate | 48 | $554 |
| Ropinirole Hcl | 17 | $466 |
| Quetiapine Fumarate | 36 | $414 |
| Zolpidem Tartrate ErZolpidem Tartrate | 13 | $345 |
| Trazodone Hcl | 74 | $323 |
| Gabapentin | 14 | $202 |
| Clonazepam | 17 | $188 |
| Temazepam | 12 | $46 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Jacksonville
- Charles BurgerJacksonville$5.6M
- Abubakr BajwaJacksonville$1.4M
- Jennifer FultonJacksonville$791K
- Sebastian Fernandez-BussyJacksonville$559K
- Remzi BagJacksonville$556K
- Jose Soto SotoJacksonville$549K
- Augustine LeeJacksonville$533K
- Jorge MalleaJacksonville$478K
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.